PREVALENCE OF NON-ALCOHOLIC FATTY LIVER DISEASE IN TYPE 2 DIABETES MELLITUS PATIENTS
Main Article Content
Keywords
Prevalence, non-alcoholic fatty liver disease, Type 2 diabetes mellitus
Abstract
Background:Nonalcoholic fatty liver disorder is more common in people with type 2 diabetes and the progression of this disease is significantly sped up by the presence of T2DM.
Objective: The aim of the study was to explore the Prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus patients.
Methodology: The current study was carried out in medicine department at Ghulam Mohammad mahar medical college hospital sukkur from March 2022 to April 2023 after taking approval from the ethical committee of the institute. A total of 136 individuals with T2DM were included in the research. Complete clinical data were collected. The degree of hepatic steatosis was measured using the controlled attenuation parameter (CAP) test. Liver steatosis was indicated by CAP cutoff values, which varied from S0, which indicates no steatosis (S), to S3. For the diagnosis of fibrosis, the cutoff values were as follows: 5.5 for no fibrosis (fibrosis stage F0), 5.5−8.0 for mild fibrosis (F1), 8.0−10.0 for moderate fibrosis (F2), 11.0−16.0 for severe fibrosis (F3), and >16.0 for cirrhosis (F4).Data was analyzed through GraphPad InStat software.
Results; A total of 136 participants were included in this study. Out of which 75(55.1%) were male and 61 (44.8%) were females. According to our results based on the CAP cut-off values. 58(42.6%) of those with T2DM had no steatosis 20(14.7%) had mild (S1, 237.0−259.0 dB/m), 26(19.1%) had moderate, and 32(23.5%) had severe steatosis. Furthermore, based on the cutoff values, 58(42.6%) of the participants had no fibrosis, 34(25%) had mild, 20(14.7%) had moderate and 13(9.5%) had sever fibrosis, 14.5% and 11(8.5%) had cirrhosis. hence a total of 57% of individuals with T2DM have NAFLD. Males have a greater prevalence of NAFLD (55.1%) than females have (44.8%).
Conclusion Individuals having Type 2 diabetes mellitus had a greater frequency of NAFLD (57%), according to our study, emphasizing the need of preventative measures.
References
2. Yamane R, Yoshioka K, Hayashi K, Shimizu Y, Ito Y, Matsushita K, et al. Prevalence of nonalcoholic fatty liver disease and its association with age in patients with type 2 diabetes mellitus. World J Hepatol 2022; 14:1226.
3. Stefan N, Cusi K. A global view of the interplay between non-alcoholic fatty liver disease and diabetes. Lancet Diabetes Endocrinol 2022; 10:284–96.
4. Dharmalingam M, Yamasandhi PG. Nonalcoholic fatty liver disease and type 2 diabetes mellitus. Indian J Endocrinol Metab 2018; 22:421.
5. Pu K, Wang Y, Bai S, Wei H, Zhou Y, Fan J, Qiao L. Diagnostic accuracy of controlled attenuation parameter (CAP) as a non-invasive test for steatosis in suspected nonalcoholic fatty liver disease: a systematic review and meta-analysis. BMC Gastroenterol 2019; 19:1.
6. Friedrich-Rust M, Romen D, Vermehren J, Kriener S, Sadet D, Herrmann E, et al.Acoustic radiation force impulse-imaging and transient elastography for noninvasive assessment of liver fibrosis and steatosis in NAFLD. Eur J Radiol 2012; 81: -325–31.
7. Chan WK, Nik Mustapha NR, Mahadeva S. Controlled attenuation parameter for the detection and quantification of hepatic steatosis in nonalcoholic fatty liver disease. J Gastroenterol Hepatol 2014; 29:1470–6.
8. Karlas T, Petroff D, Garnov N, B€ ohm S, Tenckhoff H, Wittekind C, et al. Non-invasive assessment of hepatic steatosis in patients with NAFLD using controlled attenuation parameter and 1H-MR spectroscopy. PLoS ONE 2014; 9(e):91987..
9. Ledinghen VD, Wong GL, Vergniol J, Chan HL, Hiriart JB, Chan AW, et al. Controlled Attenuation parameter for the diagnosis of steatosis in non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2016; 31:848–55.
10. Lee HW, Park SY, Kim SU, Jang JY, Park H, Kim JK, et al. Discrimination of nonalcoholic steatohepatitis using transient elastography in patients with nonalcoholic fatty liver disease. PLoS ONE 2016; 11:e0157358.
11. Chan WK, Nik Mustapha NR, Wong GL, Wong VW, Mahadeva S. Controlled attenuation parameter using the Fibro Scan XL probe for quantification of hepatic steatosis for non-alcoholic fatty liver disease in an Asian population. United European Gastroenterol J 2017; 5:76–85
12. Park CC, Nguyen P, Hernandez C, Bettencourt R, Ramirez K, Fortney L, et al. Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease. Gastroenterol 2017; 152:598–607.
13. Petta S, Wong VW, Camm a C, Hiriart JB, Wong GL, Marra F, et al. Improved noninvasive prediction of liverfibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values. Hepatol 2017; 65:1145–55.
14. Kumar M, Rastogi A, Singh T, Behari C, Gupta E, Garg H, et al. Controlled attenuation parameter for non-invasive assessment of hepatic steatosis: does etiology affect performance? J Gastroenterol Hepatol 2013; 28:1194–201. jgh.12134.
15. Mikolasevic I, Orlic L, Franjic N, Hauser G, Stimac D, Milic S. Transient elastography with controlled attenuation parameter in the assessment of liver steatosis andfibrosis in patients with nonalcoholic fatty liver disease-Where do we stand? World J Gastroenterol 2016; 22:7236
16. Kamali L, Adibi A, Ebrahimian S, Jafari F, SharifiM. Diagnostic performance of Ultrasonography in detecting fatty liver disease in comparison withfibroscan in people suspected of fatty liver. Adv Biomed Res 2019; 8:96.
17. Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, George J, Bugianesi E. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nature Rev Gastroenterol Hepatol 2018; 15:11–20. nrgastro.2017.
18. Amarapurkar D, Kamani P, Patel N, Gupte P, Kumar P, Agal S, et al. Prevalence of non-alcoholic fatty liver disease: population based study. Ann Hepatol 2007;6:161–3.
19. Kalra S, Vithalani M, Gulati G, Kulkarni CM, Kadam Y, Pallivathukkal J, et al. Study of prevalence of nonalcoholic fatty liver disease (NAFLD) in type 2 diabetes patients in India (SPRINT). J Assoc Physicians India 2013; 61:448–53.
20. Kumar L, Kumar A. Prevalence of non-alcoholic fatty liver disease and its association with diabetic nephropathy in type 2 diabetes mellitus patients. Int J Contemporary Med Surg Radiol 2020; 5:A243–6.
21. Bhatt KN, Pranav V, Dipika Y, Dharmesh N, Radhika N, Arvind S. Prevalence of nonalcoholic fatty liver disease in type 2 diabetes mellitus and its relation with insulin resistance in South Gujarat Region. J Mahatma Gandhi Institute Med Sci 2017;22(8).
22. Rohini I, Aarthi N. A study of prevalence of non -alcoholic fatty liver in type 2 diabetes mellitus patients. Int J Contemporary Med Res 2019; 6:L37–40.
23. Mohan V, Farooq S, Deepa M, Ravikumar R, Pitchumoni C1. Prevalence of nonalcoholic fatty liver disease in urban south Indians in relation to different grades of glucose intolerance and metabolic syndrome. Diabetes Res Clin Pract 2009; 84:84–91.
24. Prashanth M, Ganesh HK, Vima MV, John M, Bandgar T, Joshi SR, et al. Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. J Assoc Physicians India 2009; 57:205–10.
25. Agarwal AK, Jain V, Singla S, Baruah BP, Arya V, Yadav R, et al. Prevalence of nonalcoholic fatty liver disease and its correlation with coronary risk factors in patients with type 2 diabetes. J Assoc Physicians India 2011; 59:351–4.
26. Chen K, Sng WK, Quah JH, Liu J, Chong BY, Lee HK, et al. Clinical spectrum ofnonalcoholic fatty liver disease in patients with diabetes mellitus. PLoS ONE 2020;15:-0236977.
27. Lomonaco R, Godinez Leiva E, Bril F, Shrestha S, Mansour L, Budd J, et al. Advanced liver fibrosis is common in patients with type 2 diabetes followed in the outpatient setting: the need for systematic screening. Diabetes Care 2021; 44:399–406.
28. Tuong TT, Tran DK, Phu PQ, Hong TN, Chu Dinh T, Chu DT. Non-alcoholic fattyliver disease in patients with type 2 diabetes: evaluation of hepatic fibrosis and steatosis using fibroscan. Diagnostics 2020;10:159.
29. Younossi ZM, Golabi P, de Avila L, Paik JM, Srishord M, Fukui N, et al. The globalepidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol 2019; 71:793–801.
30. Mantovani A, Petracca G, Beatrice G, Tilg H, Byrne CD, Targher G. Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals. Gut 2021; 70:962–9.
31. Lai LL, Wan Yusoff WN, Vethakkan SR, Nik Mustapha NR, Mahadeva S, Chan WK.Screening for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography. J Gastroenterol Hepatol 2019; 34:1396– 403.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Abdul Rashid dayo
Assistant professor in medicine at Ghulam Mohammad mahar medical college hospital sukkur
Sanaullah Kalwar
Assistant Professor, Pir Abdul Qadir Shah Jilani Institue of Medical sciences, Gambat, Khairpur Mir’s
Shahab uddin Rind
Senior Registrar gastroenterology and hepatology Ghulam Mohammad mahar medical college sukkur